Rise and shine, another busy day is on the way. The events on this side of the pond, in fact, guarantee today will be rather hectic. Better than being bored, yes? So time to get cracking. The official mascot is snoozing in a corner, the short person is hunched over a laptop and the coffee kettle is whistling away. All of which makes it possible to provide the tidbits listed below. We hope your day is productive and you remain upbeat. Look on the sunny side, as they say. Stay safe, meanwhile, and wear a mask. …
The University of Oxford hopes to present late-stage trial results on its Covid-19 vaccine candidate this year, raising hopes that the U.K. could start to roll out a successful vaccine in late December or early 2021, Reuters tells us. Oxford Vaccine Trial Chief Investigator Andrew Pollard told U.K. lawmakers that determining whether or not the vaccine worked would likely come this year, after which the data would have to be carefully reviewed by regulators and then a political decision made on who should get the vaccine.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.